Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 288

1.

Infection with Chlamydia pneumoniae as a cause of coronary heart disease: the hypothesis is still untested.

Grayston JT, Belland RJ, Byrne GI, Kuo CC, Schachter J, Stamm WE, Zhong G.

Pathog Dis. 2015 Feb;73(1):1-9. doi: 10.1093/femspd/ftu015. Epub 2014 Dec 4. Review. No abstract available.

2.

Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome.

Cannon CP, Braunwald E, McCabe CH, Grayston JT, Muhlestein B, Giugliano RP, Cairns R, Skene AM; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators.

N Engl J Med. 2005 Apr 21;352(16):1646-54.

3.

Azithromycin for the secondary prevention of coronary events.

Grayston JT, Kronmal RA, Jackson LA, Parisi AF, Muhlestein JB, Cohen JD, Rogers WJ, Crouse JR, Borrowdale SL, Schron E, Knirsch C; ACES Investigators.

N Engl J Med. 2005 Apr 21;352(16):1637-45.

4.

Chlamydia pneumoniae and atherosclerosis.

Grayston JT.

Clin Infect Dis. 2005 Apr 15;40(8):1131-2. Epub 2005 Mar 14. No abstract available.

PMID:
15791512
5.

Effect of short-term antibiotic treatment on Chlamydia pneumoniae and peripheral endothelial function.

Kuvin JT, Gokce N, Holbrook M, Hunter LM, Patel AR, Sliney KA, Craven DE, Grayston JT, Keaney JF Jr, Karas RH, Vita JA.

Am J Cardiol. 2003 Mar 15;91(6):732-5. No abstract available.

PMID:
12633811
6.

Antibiotic treatment of atherosclerotic cardiovascular disease.

Grayston JT.

Circulation. 2003 Mar 11;107(9):1228-30. No abstract available.

PMID:
12628937
7.

Preclinical models for Chlamydia pneumoniae and cardiovascular disease: hypercholesterolemic mice.

Campbell LA, Moazed TC, Kuo CC, Grayston JT.

Clin Microbiol Infect. 1998 Jan;4 Suppl 4:S23-S32.

8.

Radical changes to chlamydial taxonomy are not necessary just yet.

Schachter J, Stephens RS, Timms P, Kuo C, Bavoil PM, Birkelund S, Boman J, Caldwell H, Campbell LA, Chernesky M, Christiansen G, Clarke IN, Gaydos C, Grayston JT, Hackstadt T, Hsia R, Kaltenboeck B, Leinonnen M, Ojcius D, McClarty G, Orfila J, Peeling R, Puolakkainen M, Quinn TC, Rank RG, Raulston J, Ridgeway GL, Saikku P, Stamm WE, Taylor-Robinson DT, Wang SP, Wyrick PB.

Int J Syst Evol Microbiol. 2001 Jan;51(Pt 1):249; author reply 251-3. No abstract available. Erratum in: Int J Syst Evol Microbiol. 2006 Mar;56(Pt 3):677. Ocjius, D [corrected to Ojcius, D].

PMID:
11211265
9.

Association between C-reactive protein, anti-Chlamydia pneumoniae antibodies, and vascular function in healthy adults.

Sharma N, Rutherford JD, Grayston JT, King LP, Jialal I, Andrews TC.

Am J Cardiol. 2001 Jan 1;87(1):119-21, A9.

PMID:
11137849
10.

Association of Chlamydia pneumoniae immunoglobulin A seropositivity and risk of lung cancer.

Jackson LA, Wang SP, Nazar-Stewart V, Grayston JT, Vaughan TL.

Cancer Epidemiol Biomarkers Prev. 2000 Nov;9(11):1263-6.

11.

Chlamydia pneumoniae, herpes simplex virus type 1, and cytomegalovirus and incident myocardial infarction and coronary heart disease death in older adults : the Cardiovascular Health Study.

Siscovick DS, Schwartz SM, Corey L, Grayston JT, Ashley R, Wang SP, Psaty BM, Tracy RP, Kuller LH, Kronmal RA.

Circulation. 2000 Nov 7;102(19):2335-40.

PMID:
11067785
12.

Secondary prevention antibiotic treatment trials for coronary artery disease.

Grayston JT.

Circulation. 2000 Oct 10;102(15):1742-3. No abstract available.

PMID:
11023925
13.
14.

Chlamydia pneumoniae and the risk of first ischemic stroke : The Northern Manhattan Stroke Study.

Elkind MS, Lin IF, Grayston JT, Sacco RL.

Stroke. 2000 Jul;31(7):1521-5.

PMID:
10884447
15.

What is needed to prove that Chlamydia pneumoniae does, or does not, play an etiologic role in atherosclerosis?

Grayston JT.

J Infect Dis. 2000 Jun;181 Suppl 3:S585-6. No abstract available.

PMID:
10839765
16.

Past use of erythromycin, tetracycline, or doxycycline is not associated with risk of first myocardial infarction.

Jackson LA, Smith NL, Heckbert SR, Grayston JT, Siscovick DS, Psaty BM.

J Infect Dis. 2000 Jun;181 Suppl 3:S563-5.

PMID:
10839759
17.

Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma.

Jackson LA, Campbell LA, Schmidt RA, Kuo C, Cappuccio AL, Lee MJ, Grayston JT.

J Infect Dis. 2000 Jun;181 Suppl 3:S447-8.

PMID:
10839735
18.

Chlamydia pneumoniae serology: interlaboratory variation in microimmunofluorescence assay results.

Peeling RW, Wang SP, Grayston JT, Blasi F, Boman J, Clad A, Freidank H, Gaydos CA, Gnarpe J, Hagiwara T, Jones RB, Orfila J, Persson K, Puolakkainen M, Saikku P, Schachter J.

J Infect Dis. 2000 Jun;181 Suppl 3:S426-9.

PMID:
10839729
19.

Chlamydia pneumoniae and atherosclerotic risk in populations: the role of seroepidemiology.

Siscovick DS, Schwartz SM, Caps M, Wang SP, Grayston JT.

J Infect Dis. 2000 Jun;181 Suppl 3:S417-20. Review.

PMID:
10839727
20.

Background and current knowledge of Chlamydia pneumoniae and atherosclerosis.

Grayston JT.

J Infect Dis. 2000 Jun;181 Suppl 3:S402-10. Review.

PMID:
10839724

Supplemental Content

Loading ...
Support Center